Anticancer Activity of Tetrahydrocorysamine against Pancreatic Adenocarcinoma Cell Line PANC-1 In vitro and In vivo

Jian-Bo Zhou, Gang Peng*, Jun Li, Yu-Cheng Jia, Jia Wang, Shu Nie and Qiu-Ying Zhang
Department of General Surgery, Suizhou Hospital, Hubei University of Medicine, Suizhou 441300, PR China

*For correspondence: Email: gangpeng_hb@163.com

Abstract

Purpose: To investigate the cytotoxic activity of tetrahydrocorysamine (TCSM) from Corydalis Rhizoma W. T. Wang (Papaveraceae) against PANC-1 cells and its possible mechanisms.

Methods: TCSM was isolated from Corydalis Rhizoma by column chromatography and identified by mass spectrometry and nuclear magnetic resonance (NMR). The effects of TCSM on the proliferation and apoptosis of PANC-1 cells were determined by methyl thiazolyl tetrazolium (MTT) and flow cytometry assays. The effect of TCSM on the expressions of mitochondria-mediated apoptotic proteins were investigated by Western blot assay. Xenograft assay was used to evaluate the anticancer activity of TCSM in vivo.

Results: TCSM showed cytotoxic activity against PANC-1 cells with half-maximal concentration (IC₅₀) of 19.16 μM in MTT assay. TCSM (5, 10 and 20 μM) significantly (p < 0.01) increased the apoptosis rates of PANC-1 cells (24.45, 35.26 and 54.16 vs 6.12 %), compared with control group. The results of Western blot suggest that TCSM significantly (p < 0.01) down-regulated the expressions of anti-apoptotic proteins (Bcl-2 and Survivin), up-regulated the expressions of pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) and promoted the release of cytochrome C from mitochondria to the cytoplasm of PANC-1 cells, compared with control. TCSM (20 mg/kg) significantly (p < 0.01) inhibited the growth of PANC-1 cell-induced tumor (384 vs 1138 mm³) by regulating the expressions of mitochondria-mediated apoptotic proteins as stated above for xenograft assay, compared with control.

Conclusion: TCSM induces apoptosis in PANC-1 cells in vitro and in vivo via mitochondria-mediated apoptotic pathway.

Keywords: Corydalis Rhizoma, Tetrahydrocorysamine, PANC-1 cells, Flow cytometry, Western blot, Xenograft

INTRODUCTION

Currently, pancreatic adenocarcinoma is still a major unsolved health problem, and almost all pancreatic adenocarcinoma patients suffer from metastases and deaths [1]. The pancreatic adenocarcinoma is usually diagnosed in the advanced state, when there are few or no effective therapies, so the 5-year survival rate of pancreatic adenocarcinoma patients remains poor (about 3 %) [2]. Therefore, it is urgent and important to find new, safety and effective drugs for treating pancreatic adenocarcinoma. Nowadays, finding compounds from plants are an important pathway to obtain new drugs for treating pancreatic adenocarcinoma [3].
Corydalis Rhizoma [Corydalis yanhusuo W. T. Wang (Papaveraceae)] is a commonly used medicine in China, and its major constituents are alkaloids such as d-corydalone, dl-tetrahydropalmatine, protopine, berberine, l-tetrahydrocoptisine, dl-tetrahydrocoptisine, l-tetrahydrocolumbamine, d-corybulbine, d-glaucine, a-allocoptine and tetrahydrocorysamine (TCSM) [4]. It is reported that Corydalis Rhizoma has anticanic activity [5], and the active constituents are the alkaloids [6]. The anticancer activities of alkaloids from Corydalis Rhizoma have been widely reported [7,8], and the mechanisms involve apoptosis, reversal of multidrug resistance of tumor cells, anti-angiogenic effect, the expression of microRNAs, etc.

In the present study, we investigated the cytotoxic activity of TCSM isolated from Corydalis Rhizoma against PANC-1 cells and possible mechanisms by methyl thiazolyl tetrazolium (MTT), flow cytometry, Western blot and xenograft assays.

**EXPERIMENTAL**

**Plant materials**

Corydalis Rhizoma was purchased from Anguo Chinese herbal medicine market (Hebei, China) in 2013, identified by Gang Peng, Suizhou Hospital, Hubei University of Medicine. A voucher specimen (voucher no. 201309113) was stored in Hubei University of Medicine for future reference.

**Chemicals and reagents**

Silica gel (300 - 400 mesh), all analytical grade reagents including ethanol, petroleum ether, chloroform, ethyl acetate and n-butyl alcohol, acetone and preparative TLC were purchased from Qingdao Haiyang Chemical Co., Ltd. (Qingdao, China). DMEM medium and fetal bovine seraums (FBS) were obtained from Invitrogen (Carlsbad, CA, USA). MTT Cell Proliferation and Cytotoxicity Assay Kits and Enhanced BCA Protein Assay Kit were obtained from Applygen (Beijing, China) and Beyotime Institute of Biotechnology (Shanghai, China). Annexin V-FITC/PI apoptosis assay kits were purchased from Ruisai biomart (Shanghai, China). Primary antibodies for β-actin, Bcl-2, Survivin, Bax, Smac, cytochrome c, cleaved caspase-3 (c-caspase-3), c-caspase-9 and horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody were purchased form Cell Signaling Technology (Beverly, MA, USA).

**Animals**

Nude mice (BALB/C, 5 - 6 weeks old) were purchased from the SLRC Laboratory Animal Company (Shanghai, China). All experiments were strictly in accordance with international ethical guidelines and the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals [9] and carried out with the approval of the Animal Experimentation Ethics Committee of Suizhou Hospital, Hubei University of Medicine (protocol no: HBUMSZH2014).

**Preparation of TCSM**

The air-dried Corydalis Rhizoma (120 kg) was finely ground and extracted by refluxing with 85 % ethanol. The ethanol solvent was evaporated under reduced pressure to obtain a crude extract, which was then suspended in water and partitioned with petroleum ether, chloroform, ethyl acetate and n-butyl alcohol. The petroleum ether fraction (1025 g) was subjected to column chromatography over silica gel (300 - 400 mesh), eluted with petroleum ether-acetone (99:1 - 40:60) to give 31 fractions. Fraction 8 (51.2 g) was separated by column chromatography over silica gel (petroleum ether-ethyl acetate) and further isolated by preparative TLC (petroleum ether-acetone) to afford TCSM (204 mg). The purity and structure of TCSM were verified and identified by HPLC, mass spectrometry and NMR. Additionally, the extraction and isolation were performed many times in order to obtain enough TCSM.

**Cell culture**

PANC-1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and routinely cultured in DMEM medium supplemented with 10 % FBS, 100 U/mL penicillin and 100 U/mL streptomycin at 37 °C in 5 % CO₂ and 95 % O₂.

**MTT assay**

The cytotoxic activity of TCSM against PANC-1 cells was evaluated by MTT assay. PANC-1 cells were seeded on 96-well culture plates with DMEM medium. After 24 h of incubation, cells were treated with TCSM at concentrations of 0 (for control), 5, 10, 15, 20, 25 and 30 μM. After 48 h, MTT was added into every well, and cells were cultured at 37 °C in 5 % CO₂ and 95 % O₂ for another 3 h. Then the optical density (OD) was measured at 570 nm with a micro plate reader (Thermo, USA). The inhibition rate of TCSM against PANC-1 cells could be determined by the following equation: inhibition
rate (%) = (OD control – OD treatment)/OD control × 100 %.

Flow cytometry analysis
After treatment with TCSM at concentrations of 0 (for control), 5, 10, and 20 μM for 48 h, PANC-1 cells were collected and washed with phosphate buffered saline (PBS, 0.2 mol/L, pH = 7.0). Then the washed PANC-1 cells were re-suspended in staining buffer and stained with Annexin V-FITC/PI, and the PANC-1 cells were quantified by flow cytometry and analyzed by the Cell Quest Acquisition software (FACS Calibur, Becton Dickinson, USA).

Western blot analysis
After treatment with TCSM at concentrations of 0 (for control), 5, 10, and 20 μM for 48 h, total proteins of PANC-1 cells were extracted, and their concentration was determined by an Enhanced BCA Protein Assay Kit. Then, total protein (35 μg) were separate by SDS/PAGE and transferred onto a PVDF membrane. After blocking with 5 % fat-free milk, the membranes were incubated with primary antibodies including anti-β-actin, anti-Bcl-2, anti-Survivin, anti-Bax, anti-Smac, anti-cytochrome c, anti-c-caspase-3, anti-c-caspase-9 at 4 °C overnight. Membrane was washed with Tris buffered saline-Tween (TBS-T) and further incubated with HRP-conjugated secondary antibody for 1 h at room temperature in TBS-T. After another rinse, all proteins were detected by chemiluminescence. Additionally, β-actin was selected as an inner control to assess protein loading.

Tumor xenograft model
PANC-1 cells (2 × 10^6 cells/nude mouse) were subcutaneously injected in the right flank of nude mice to establish the tumor xenograft model. When the tumor size grew to 2 - 3 mm in diameter, nude mice were randomly divided into control and treatment groups (n = 10) and given the following treatments: control group (0.5 % DMSO, intraperitoneal injection, ip) and treatment group (20 mg/kg TCSM, dissolved in 0.5 % DMSO, ip) once a day for 20 days. The body weight and tumor sizes (length and width) of nude mice were measured every 5 days with a vernier caliper, and the tumor volumes were calculated by the formula: tumor size (volume) = 0.52 × length (mm) × width^2 (mm^2) [10]. Finally, the tumor tissues of nude mice were removed, collected and used to determine the expressions of Bcl-2, Survivin, Bax, Smac, c-caspase-3, c-caspase-9 by western blot assay as described above.

Statistical analysis
All data are presented as mean ± standard deviation (SD). One-way ANOVA was used to analyze differences between control and treatment groups by Dunnett test with the aid of SPSS 21.0. Differences were recognized as statistically significant at p < 0.05.

RESULTS
Identity and purity of TCSM

The results of mass spectrometry indicated that the molecular formula of target analyte was C_{20}H_{19}NO_{4}. Comparing the NMR data of target analyte with existing literature [11], the target analyte, a colorless pinnate crystal, was identified as TCSM. ¹H-NMR (400 MHz, CDCl₃, δ: 6.54 (1H, s, H-1), 6.47 (1H, s, H-4), 2.48-3.20 (4H, m, H-5, H-6), 3.38 (1H, d, J = 15.2 Hz, H-8), 3.98 (1H, d, J = 15.2 Hz, Hb-8), 6.57 (1H, d, J = 8.1 Hz, H-11), 6.58 (1H, d, J = 8.1 Hz, H-12), 3.34 (1H, br. q, J = 6.9 Hz, H-13), 3.81 (1H, br. s, H-14), 5.90 and 5.98 (2H, d, J = 1.4 Hz, 2, 3 - OCH₂O₂), 5.96 and 6.05 (2H, d, J = 1.4 Hz, 9, 10 -OCH₂O₂), 1.04 (3H, d, J = 6.6 Hz, H-13-CH₃); ¹³C-NMR (100 MHz, CDCl₃, δ: 105.3 (C-1), 146.0 (C-2), 145.4 (C-3), 10.7.8 (C-4), 129.5 (C-4a), 29.4 (C-5), 50.8 (C-6), 52.9 (C-8), 116.3 (C-8a), 142.7 (C-9), 144.3 (C-10), 106.4 (C-11), 121.0 (C-12), 135.9 (C-12a), 38.4 (C-13), 63.4 (C-14), 129.7 (C-14a), 100.5 (2, 3 –OCH₂O₂), 100.9 (9, 10 –OCH₂O₂), 18.4 (13-CH₃). The chemical structure of TCSM is shown in Figure 1. The purity of TCSM was more than 95.3 %, which was determined by HPLC area normalization method.

Figure 1: Chemical structure of TCSM
Cytotoxic activity of TCSM against PANC-1 cells

The results of MTT assay indicated that the inhibition rates of TCSM in PANC-1 cells were between 9.28 and 83.23 %, and the IC50 value was 19.16 μM. Namely, TCSM showed good cytotoxic activity against PANC-1 cells. The results are shown in Figure 2.

Figure 2: Cytotoxic activity of TCSM against PANC-1 cells

TCSM induces apoptosis in PANC-1 cells

Flow cytometry was used to study whether the cytotoxic activity of TCSM against PANC-1 cells was related to apoptosis. The results of flow cytometry suggested that the cytotoxic activity of TCSM was related to apoptosis. As shown in Figure 3, the apoptosis rates were 6.12, 24.45, 35.26 and 54.16 % after treatment with TCSM at concentrations of 0 (for control), 5, 10 and 20 μM, and compared with the control group, the apoptosis rates of TCSM groups were significantly (p < 0.01) increased.

Effects of TCSM on the expressions of mitochondria-mediated apoptotic proteins

Western blot was used to study the pro-apoptotic mechanism of TCSM in PANC-1 cells. As shown in Figures 4 and 5, after PANC-1 cells were treated with TCSM at concentrations of 5, 10 and 20 μM, the expressions of anti-apoptotic proteins (Bcl-2 and Survivin) were significantly (p < 0.01) down-regulated, the expressions of pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) were significantly (p < 0.01) up-regulated, and the release of cytochrome c from the mitochondria to the cytoplasm was significantly (p < 0.01) promoted, compared with the control group.

Figure 3: Effect of TCSM on apoptosis in PANC-1 cells; **p < 0.01, compared with the control group
Figure 4: Effect of TCSM on anti-apoptotic proteins (Bcl-2 and Survivin) and pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) in vitro; **p < 0.01, compared with the control group.

Figure 5: Effect of TCSM on the release of cytochrome c from the mitochondria to the cytoplasm; Cytochrome c (M): cytochrome c in mitochondria; Cytochrome c (C): cytochrome c in cytoplasm; **p < 0.01, compared with the control group.

Effects of TCSM on PANC-1 cell-induced xenograft model

PANC-1 cell-induced xenograft model was used to confirm whether TCSM could inhibit the growth of PANC-1 cell-induced tumor and regulate the expressions of apoptotic proteins in vivo. The results of xenograft assay indicated that TCSM (20 mg/kg once a day for 20 day) significantly (p < 0.05 or 0.01) inhibited the growth of PANC-1 cell-induced tumor without any effect on the body weight of the nude mice during the 20 days'
observation period, compared with the control group. Moreover, the results of western blot of tumor issues indicated that TCSM significantly ($p < 0.01$) down-regulated the expressions of anti-apoptotic proteins (Bcl-2 and Survivin) and up-regulated the expressions of pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) in vivo, compared with the control group. The results are shown in Figures 6 and 7.

**Figure 6:** Effect of TCSM on tumor growth and body weight of nude mice bearing PANC-1 cells xenograft; *$p < 0.05$, **$p < 0.01$, compared with the control group.

**Figure 7:** Effect of TCSM on anti-apoptotic proteins (Bcl-2 and Survivin) and pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) in vivo; **$p < 0.01$, compared with the control group.
DISCUSSION

In the present study, we investigated the cytotoxic activity of TCSM against PANC-1 cells and possible mechanisms of action for the first time by MTT, flow cytometry, Western blot and xenograft assays.

MTT assay is a commonly used method to study the cytotoxic activity of compound against cells in vitro [12]. Flow cytometry is a commonly used method to investigate whether the cytotoxic activity of compound is related to apoptosis [13]. The results of MTT assay (Figure 2) indicated that TCSM showed good cytotoxic activity against PANC-1 cells with an IC50 of 19.16 μM. The results of flow cytometry assay (Figure 3) confirmed that the cytotoxic activity of TCSM against PANC-1 cells was related to apoptosis.

Western blot is a commonly used method to explore anticancer mechanism at the protein level, and the effect of compound on tumor growth and body weight of nude mice are two important indices in vivo [14,15]. Proteins including Bcl-2, Survivin, Bax, Smac, cytochrome c, c-caspase-3 and c-caspase-9 are very important markers in mitochondria-mediated apoptotic pathway [16]. The relations among these apoptotic proteins are rather complex and described as follows [17-21]. When cells suffer from apoptotic stimuli, pro-apoptotic proteins (Smac and cytochrome c) are released from the mitochondria to the cytoplasm, but their release can be inhibited by anti-apoptotic protein (Bcl-2). However, the function of Bcl-2 can be inhibited by pro-apoptotic protein (Bax).

Cytochrome c along with apoptotic protease activating factor-1 (Apaf-1), caspase-9 and ATP can form apoptosome in the cytoplasm to activate caspase-9 (c-caspase-9), and then c-caspase-9 can promote the activation of caspase-3 (c-caspase-3), which can lead to apoptosis of cells. The results of western blot assay (Figures 4 and 5) suggested that TCSM down-regulated the expressions of anti-apoptotic proteins (Bcl-2 and Survivin), up-regulated the expressions of pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) and promoted the release of cytochrome c from the mitochondria to the cytoplasm in PANC-1 cells.

The results of the xenograft assay (Figures 6 and 7) in nude mice indicated that TCSM inhibited the growth of PANC-1 cell-induced tumor without any effect on the body weight of the nude mice by regulating the expressions of mitochondria-mediated apoptotic proteins in vivo as described above.

CONCLUSION

TCSM exhibits cytotoxic activity against PANC-1 cells in vitro and in vivo through mitochondria-mediated apoptotic pathway. Further investigation into the mechanism of action of TCSM is required.

CONFLICT OF INTEREST

The authors declare no conflict of interest associated with this work.

CONTRIBUTION OF AUTHORS

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Jian-Bo Zhou, Gang Peng, Jun Li and Yu-Cheng Jia conceived, designed and carried out the study and written the manuscript. Jia Wang, Shu Nie and Qiu-Ying Zhang collected and analyzed the data.

REFERENCES

1. Li DH, Xie KP, Wolff R, Abruzzese JL. Pancreatic cancer. The Lancet 2004; 363: 1049-1057.
2. Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67(3): 1030-1037.
3. Lau ST, Lin ZX, Liao YH, Zhao M, Cheng CHK, Leung PS. Brucein D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer Lett 2009; 281(1): 42-52.
4. Wang XL, Zheng Z, Hong ZY, Fan GR. Advancements on chemical components and quality control of Rhizoma Corydalis. Lishizhen Med Mater Med Res 2011; 22: 227-229.
5. Gao JL, He TC, Li YB, Wang YT. A traditional Chinese medicine formulation consisting of Rhizoma corydalis and Rhizoma Curcumae exerts synergistic anti-tumor activity. Oncol Rep 2009; 22(5): 1077-1083.
6. Zhang GD, Xie L, Yu LX, Hu WJ, Qian XP, Liu BR. Antiproliferation effect of total alkaloids fraction of Yahuosuo on six human gastric cancer cell lines in vitro. Chin J Integr Trad West Med Dig 2009; 17: 81-85.
7. Piyanuch R, Sukhthankar M, Wandee G, Baek, SJ. Berberine, a natural isoquinoline alkaloids, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 2007; 258(2): 230-240.
8. Gao JL, Shi JM, Lee SMY, Zhang QW, Wang YT. Angiogenic pathway inhibition of corydalis yanhusuo and berberine in human umbilical vein endothelial cells. Oncol Rep 2009; 17(11-12): 519-526.

Trop J Pharm Res, January 2016; 15(1): 147
9. The National Research Council of The National Academy of Sciences. Guide for the Care and Use of Laboratory Animals: Eight Edition. Washington, D.C.: The National Academies Press; 2010.

10. Zhao YL, Zhao LJ, Luo YX, Li X, Zhang YF, Liu XD, Luo YG, Zhong LL. Synergistic effect of radiation and traditional Chinese medicine Rhizoma Typhonii ethanol extract depends on p53 expression in treatment of lewis mouse lung cancer cells. Afr J Tradit Complement Altern Med 2015; 12(1): 109-114.

11. Wang HS, Yang HR. The alkaloids of Corydalis dasypertem maxim. Nat Prod Res Dev 1997; 9(1): 37-39.

12. Yang QH, Yang J, Liu GZ, Wang L, Zhu TC, Gao HL, Kou XG. Study on in vitro anti-tumor activity of Bidens bipinnata L. extract. Afr J Tradit Complement Altern Med 2013; 10(3): 543-549.

13. Yuan JL, Wang SM, Lan T, Liu JZ, Wang GH, Sun QS, Chen H. Studies on anti-hepatoma effect of Gan-Ai-Xiao decoction. Trop J Pharm Res 2015; 14(7): 1249-1255.

14. Liu HY, Zhu YJ, Zhang T, Zhao ZG, Zhao Y, Cheng P, Li H, Gao H, Su XM. Anti-tumor effects of atracylenolide I isolated from Atrctyloides macrocephala in human lung carcinoma cell lines. Molecules 2013; 18(11): 13357-13368.

15. Yang XK, Xu MY, Xu GS, Zhang YL, Xu ZX. In vitro and in vivo antitumor activity of scutebarbatine A on human lung carcinoma A549 cell lines. Molecules 2014; 19(7): 8740-8751.

16. Shi YG. A structural view of mitochondria-mediated apoptosis. Nat Struct Biol 2001; 8(5): 394-401.

17. Deng YB, Lin YH, Wu XW. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Gene Dev 2002; 16(1): 33-45.

18. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma. Nat Med 1997; 3(8): 917-921.

19. Du CY, Fang M, Li YC, Li LL, Wang XD. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102(1): 33-42.

20. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P, Flavell RA. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94(3): 325-337.

21. Lakhani SA, Masud A, Kuida K, Porter Jr GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA. Caspase 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311(5762): 847-851.